Amedisys Inc (NASDAQ:AMED) was upgraded by Mizuho from a “neutral” rating to a “buy” rating in a research report issued on Thursday, November 2nd, MarketBeat Ratings reports. The brokerage presently has a $65.00 target price on the health services provider’s stock, up from their prior target price of $55.00. Mizuho’s price objective suggests a potential upside of 13.22% from the company’s previous close.
Several other research analysts also recently commented on the stock. BidaskClub downgraded shares of Amedisys from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Robert W. Baird restated a “hold” rating and issued a $50.00 target price on shares of Amedisys in a report on Wednesday, October 4th. Bank of America Corporation initiated coverage on shares of Amedisys in a report on Monday, August 21st. They issued a “neutral” rating and a $55.00 target price on the stock. Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $60.00 target price on shares of Amedisys in a report on Friday, September 15th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $60.00 price target on shares of Amedisys in a report on Thursday, October 12th. Six research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $61.00.
Amedisys (AMED) opened at $57.41 on Thursday. The company has a current ratio of 1.33, a quick ratio of 1.33 and a debt-to-equity ratio of 0.16. Amedisys has a 1 year low of $38.00 and a 1 year high of $65.91. The firm has a market cap of $1,910.64, a PE ratio of 26.94, a price-to-earnings-growth ratio of 1.36 and a beta of 0.68.
Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Tuesday, November 7th. The health services provider reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.54 by $0.02. The company had revenue of $380.20 million during the quarter, compared to analyst estimates of $384.59 million. Amedisys had a net margin of 2.88% and a return on equity of 14.68%. Amedisys’s revenue was up 5.1% compared to the same quarter last year. During the same period last year, the business earned $0.36 earnings per share. sell-side analysts expect that Amedisys will post 2.23 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by BBNS and is owned by of BBNS. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://baseballnewssource.com/markets/amedisys-inc-amed-lifted-to-buy-at-mizuho/1751019.html.
Several large investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in Amedisys by 2,877.7% in the 1st quarter. BlackRock Inc. now owns 5,676,870 shares of the health services provider’s stock worth $290,032,000 after purchasing an additional 5,486,225 shares during the period. Point72 Asset Management L.P. boosted its stake in Amedisys by 337.0% in the 3rd quarter. Point72 Asset Management L.P. now owns 474,044 shares of the health services provider’s stock worth $26,528,000 after purchasing an additional 674,044 shares during the period. American Century Companies Inc. boosted its stake in Amedisys by 41.4% in the 3rd quarter. American Century Companies Inc. now owns 1,671,680 shares of the health services provider’s stock worth $93,547,000 after purchasing an additional 489,220 shares during the period. Wells Fargo & Company MN boosted its stake in Amedisys by 29.7% in the 3rd quarter. Wells Fargo & Company MN now owns 1,484,041 shares of the health services provider’s stock worth $83,048,000 after purchasing an additional 339,825 shares during the period. Finally, Russell Investments Group Ltd. boosted its stake in Amedisys by 662.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 276,808 shares of the health services provider’s stock worth $17,387,000 after purchasing an additional 240,513 shares during the period. Institutional investors own 94.62% of the company’s stock.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with our FREE daily email newsletter.